HY-0002a
/ Huiyu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 06, 2024
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
(clinicaltrials.gov)
- P1/2 | N=257 | Recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1